Shereen Oon - Concepedia

Author

Shereen Oon

The University of Melbourne ORCID

Also Known As

S Oon, S. Oon, S.F. Oon, Sayed Fayez, Senn L Oon, Seong-Duck oon, Shereen Oon

Publications

993

Citations

H-Index

Concepts

All Affiliations

The University of Melbourne Monash University St Vincent's Hospital Melbourne National University Hospital University of Santo Tomas Hospital

About

Shereen Oon is an author at The University of Melbourne specializing in medicine, lupus, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	184
2	Epidemiology	3	3	99
3	Public Health	2	2	77
4	Allergy	1	1	33
5	Cell Biology	1	1	33

Shereen Oon

Publications

607

Citations

H-Index

Page 1

	Year	Citations
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus Shereen Oon, Molla Huq, Vera Golder, Annals of the Rheumatic Diseases	2019	89
Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study Rangi Kandane‐Rathnayake, Vera Golder, Worawit Louthrenoo, The Lancet Rheumatology Longitudinal Cohort StudyAutoimmune DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus TreatmentLupus	2022	56
Bcl‐2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus‐Prone Mice and Dampen Interferon‐α Production Yifan Zhan, Emma M. Carrington, Hyun‐Ja Ko, Arthritis & Rheumatology	2014	48
Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus Sharzad Emamikia, Shereen Oon, Alvaro Gómez, Lara D. Veeken	2022	43
‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study Rangi Kandane‐Rathnayake, Worawit Louthrenoo, Alberta Hoi, Arthritis Research & Therapy	2022	42
A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus Shereen Oon, Huy Huynh, Tsin Yee Tai, JCI Insight ImmunologyImmune RegulationImmunologic MechanismImmunotherapeuticsCd4 T Cell Responses	2016	33
Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE Cynthia Aranow, Anca Askanase, Shereen Oon, Annals of the Rheumatic Diseases	2020	26
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study Yasuhiro Katsumata, Eisuke Inoue, Masayoshi Harigai, Annals of the Rheumatic Diseases	2024	26
A potential association between IL‐3 and type I and III interferons in systemic lupus erythematosus Shereen Oon, Katherine Monaghan, Milica Ng, Clinical & Translational Immunology	2019	25
Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study Jiacai Cho, Liang Shen, Molla Huq, The Lancet Rheumatology Low Disease ActivityAutoimmune DiseaseSystemic Lupus ErythematosusSystemic Lupus Erythematosus TreatmentLupus	2023	24

Page 1